Tag: Competition

Displaying 161 - 180 of 2270 results.

Pages

Federal Trade Commission staff submitted a comment, as public testimony, to the Alaska legislature on proposed legislation that would allow licensed Alaska physicians located out-of-state to provide telehealth services in the same manner as in-state physicians. 
Federal Trade Commission staff submitted a comment on the competitive implications of proposed legislation that would license and regulate denturists within Kentucky.  Denturists are trained to make and fit removable partial and full dentures. Currently, Kentuckians who need dentures must obtain...
Julie Brill, who has served as a Commissioner of the Federal Trade Commission since April 2010, will resign her position at the end of this month. “Commissioner Brill has been an unwavering advocate for consumers and competition during her six-year tenure at the Federal Trade Commission,” said FTC...
Federal Trade Commission Chairwoman Edith Ramirez issued the following statement regarding the Supreme Court’s denial of certiorari in McWane Inc. v. FTC. The Court declined to review an April 2015 decision of the Eleventh Circuit upholding a Commission cease and desist order against McWane for...
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that national kidney-dialysis chain U.S. Renal Care, Inc.’s $640 million acquisition of competitor DSI Renal from DSI Renal’s ultimate parent company, Dialysis Parent, LLC, would be...
The Federal Trade Commission filed an amicus brief with the U.S. Court of Appeals for the Third Circuit urging the court to correct four legal errors in a district court’s antitrust analysis of an alleged reverse-payment agreement involving brand-name pharmaceutical company GlaxoSmithKline and...
From: Whitehead, NoraSent: Thursday, March 03, 2016 11:12 AMTo: [REDACTED]Cc: Gillis, Diana L.; Walsh, Kathryn E.Subject: RE: 801.10, 801.30  Confirmed. From: [REDACTED]Sent: Thursday, March 03, 2016 10:02 AMTo: Whitehead, Nora; Gillis, Diana L.Cc: Walsh, Kathryn E.Subject: 801.10,...
Brief of the Federal Trade Commission arguing that the district court committed multiple legal errors that should be corrected on appeal. The district court erroneously concluded that a reverse-payment settlement that allowed the underlying patent litigation to continue, while the...
Federal Trade Commission staff submitted written comments on the competitive impact of provisions in proposed legislation in West Virginia that would provide for  “cooperative agreements” between health care providers, and provisions purporting to confer “exemptions” from federal antitrust laws on...
Ten years ago this month, the FTC and DOJ issued the Commentary on the Horizontal Merger Guidelines.
Testifying on behalf of the Federal Trade Commission before the U.S. Senate Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights, Chairwoman Edith Ramirez outlined how effective antitrust enforcement benefits both consumers and businesses by preventing mergers and business...
The FTC issued an administrative complaint alleging that the proposed merger of Advocate Health Care Network and NorthShore University HealthSystem will create the largest hospital system in the North Shore area of Chicago.  According to the complaint, the combined entity would...
Drug manufacturer Hikma Pharmaceuticals PLC agreed to sell the rights and assets for two generic drugs, and relinquish its U.S. marketing rights to a third generic drug, in order to settle FTC charges that its proposed $2 billion acquisition of Roxane would likely be anticompetitive...
There is a basic but important difference between antitrust cases brought by the government and those brought by private parties: All plaintiffs, including government enforcers like the FTC, must prove an antitrust violation, which requires showing harm to competition. But private...
Drug manufacturer Hikma Pharmaceuticals PLC will sell the rights and assets for two generic drugs, and relinquish its U.S. marketing rights to a third generic drug, in order to settle FTC charges that Hikma’s proposed $2 billion acquisition of Roxane would likely be anticompetitive.
The FTC issued an administrative complaint and authorized staff to seek a preliminary injunction to enjoin the transaction pending the results of the administrative proceeding, charging that Staples, Inc.’s proposed $6.3 billion acquisition of Office Depot, Inc. would  significantly...

Pages